Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2-overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

S. Glück

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2-overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial'. Together they form a unique fingerprint.